CARLSBAD, Calif. – Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, announced the receipt of a novel, induced pluripotent stem cell (iPSC) line containing hypoimmunity edits, from Factor Bioscience Inc. (“Factor”). Generation of the line marks a successful milestone in the strategic collaboration between the two companies, under which Factor developed a proprietary, genetically engineered iPSC line that Lineage can utilize for differentiation into certain cell transplant product candidates. [Read more…]
Cellistic Launches Three New iPSC-based GMP Manufacturing Platforms to advance Immuno-Oncology and Regenerative Cell Therapies
Kobe University Introduces a Simplified Cryopreservation Method for iPSCs
Researchers at Kobe University have unveiled a novel cryopreservation technique that could meaningfully streamline how induced pluripotent stem cells (iPSCs) are stored and handled in laboratory settings. The newly reported method allows iPSCs to be frozen directly within standard culture dishes, eliminating the need for cell transfer prior to cryostorage, an advancement that may significantly improve workflow efficiency across stem cell research, drug discovery, and regenerative medicine. [Read more…]
GMP Manufacturing of iPSC Master Cell Banks for Allogeneic Therapies at REPROCELL:
A Cost-Optimized Approach
Are you advancing an iPSC therapy program and planning for clinical-scale manufacturing of GMP Master Cell Banks (MCBs)? REPROCELL provides industry-standard, GMP-compliant iPSC MCB manufacturing services that support robust regulatory pathways without compromising quality or operational discipline. Through our European partnership with Histocell and its EMA-authorized facility in Bilbao, Spain, together with REPROCELL’s U.S. GMP site in Beltsville, Maryland, we offer a dual-site manufacturing network aligned with FDA, EMA, and PMDA expectations.
This infrastructure provides the scale, regulatory alignment, and global flexibility needed for allogeneic therapy programs moving to clinical translation without the excessive costs often linked to iPSC GMP manufacturing. [Read more…]
4 Major Areas of Commercialization for iPS Cells
Since the discovery of induced pluripotent stem cells in 2006, a great deal of basic research has been done to understand how to produce, manipulate, and utilize the stem cell type. In addition to this important basic research, a great deal of applied (“translational”) results has been done with the cell type. Induced pluripotent stem cells (also called iPS cells or iPSCs) are revolutionizing regenerative medicine because they represent a potential route for producing patient-specific stem cells for research or clinical use.
In the future, iPS cells will facilitate progress in personalized medicine by allowing a patient to use his or her own cells. In addition, iPSCs also show great promise in other areas, such as phamaco-toxicological screening, by allowing disease modeling and safety assessment of potential new drugs under development, in short, facilitating the study of a “disease in a dish.”
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 20
- Next Page »




